Home › Market › 2026-10-05

US Stock Analysis and Analyst Forecasts — October 5, 2026

The S&P 500 rose 0.67%, the Dow 0.18% and the Nasdaq 100 0.87% to a record close as Brent crude fell back to about $99 and the 10-year Treasury yield hit a 24-year high of 5.32%; PTC jumped 33% on a $22.6 billion takeover by Schneider Electric, Stifel lifted its AMD target to $700, Bank of America upgraded DraftKings, and Intel slid on reports that Tesla is in talks to bring TSMC into its Terafab project.

None of the following is our own view on any stock — it is a same-day record of market action, analyst-firm calls and company news across the tracked universe on Monday, October 5, 2026.

U.S. stocks started the week higher as technology shares rallied and oil kept retreating. The S&P 500 gained 0.67% to 7,774.22, the Dow Jones Industrial Average added 0.18% to 51,267.90 and the Nasdaq 100 climbed 0.87% to 31,076.44, a record close, leaving the tech-heavy index up about 23% for the year. Brent crude fell 2.2% to about $99 a barrel as Middle East crude exports moved back toward pre-war levels and Saudi-backed Yemeni forces retook areas near the Bab el-Mandeb Strait from Houthi fighters. The rally came despite another push higher in bond yields: the 10-year Treasury yield rose 4.7 basis points to 5.32%, its highest level in 24 years, and the 30-year reached 5.67%. The ISM services index for September came in at 54.9, down from 55.4 in August and slightly below the 55 economists expected, though it marked a 27th straight month of expansion.

Materials led the sectors with a 1.22% gain. Vylor, the crop-protection business just spun out of Corteva, led the group on its first day of trading after Bank of America (BAC) started coverage with a Buy rating and a $78 target; both Vylor and Corteva are outside the tracked universe, as are steelmakers Nucor and Steel Dynamics, which rose with copper and steel prices. Freeport-McMoRan (FCX) was among the gainers. Real estate was the weakest sector, down 0.42%, as the jump in Treasury yields raised financing costs for rate-sensitive property trusts and made their dividend yields less attractive against government bonds.

PTC, outside the tracked universe, was the best performer in the S&P 500, surging about 33% after France's Schneider Electric agreed to buy the industrial-software company for $22.6 billion, or $205 a share, in a deal expected to close in the third quarter of 2027. Analyst firms promptly moved to the sidelines: Oppenheimer cut the stock to Perform from Outperform, Deutsche Bank went to Hold from Buy, Barclays moved to Equal Weight from Overweight and JPMorgan lifted it to Neutral from Underweight, all reflecting that the shares now trade near the agreed price.

In semiconductors, Stifel raised its Advanced Micro Devices (AMD) price target to $700 from $635 ahead of the company's fiscal third-quarter report, saying it expects results to beat estimates and guidance to move higher. Intel (INTC) fell about 2.6% after Tesla (TSLA) chief executive Elon Musk confirmed on X that the carmaker is in discussions with Taiwan Semiconductor (TSM) about joining its Terafab chip-manufacturing project, calling them 'just discussions' while allowing that something may come of them; Intel had been positioned as the project's main producer. A separate survey put AMD's share of the CPU market at 48.4%, up from just under 45% in May. Intel's consensus is a Hold from 30 analysts with a $114.38 average target, slightly below the current price. Taiwan Semiconductor rose about 2.75%.

Nvidia (NVDA) gained about 2.1% and traded near $240, a level one widely followed investor identified as the threshold for a breakout, even as two former Groq engineers filed a lawsuit in Delaware's Court of Chancery on October 2 over Nvidia's $20 billion Groq transaction. The complaint alleges Groq's board approved the deal without a required stockholder vote and that assigning $17 billion to a non-exclusive technology license and $3 billion to Nvidia restricted stock for transferring employees left remaining stockholders short-changed; Groq called the suit meritless. Nvidia's consensus is a Strong Buy from 32 analysts with a $325.03 average target, about 36% above the current price. Micron (MU) slipped about 1% as it continued to digest last week's earnings, though it remains up roughly 273% this year; its consensus average target is $1,581.40 from 26 analysts.

Microsoft (MSFT) rose about 1.5% and Meta Platforms (META) about 1.9% despite reports that both have told employees to cut back on Anthropic's Claude Code coding tool. Meta's internal user count has reportedly fallen to about 30,000 from 60,000, though it still spent roughly $105 million on the tool over a recent 28-day period, and Microsoft is said to have trimmed its Anthropic spending by about a third in favor of in-house products. Neither company confirmed the reports, which arrived as Anthropic prepares an initial public offering reportedly targeted before Thanksgiving at a $2 trillion valuation. Microsoft's consensus is a Strong Buy from 37 analysts with a $558.86 average target. Apple (AAPL) was the only member of the Magnificent Seven in the red.

Among other company news, General Motors (GM) climbed about 2.5% after a propulsion executive told CNBC the company will add more hybrids to its U.S. lineup as hybrid sales grow 23% year over year to a record 16.3% of the market while electric vehicles hold about 5.8%; GM currently sells only one U.S. hybrid, a Corvette variant, and industry forecasters expect its plug-in hybrids from late 2027. GM's consensus is a Strong Buy from 15 analysts with a $110.73 average target. Bank of America upgraded DraftKings, outside the tracked universe, to Buy from Hold with a $27 target, arguing that prediction markets are growing more slowly than sportsbooks by amount wagered; the stock jumped more than 6% but remains down about 43% this year. Telsey reiterated a Buy rating and a $1,135 target on Costco (COST) ahead of Wednesday's September sales report, forecasting 10.1% comparable-sales growth. Eli Lilly (LLY) edged up after the FDA granted orphan-drug status to olomorasib, its experimental KRAS G12C cancer drug that already holds breakthrough designation for a form of pancreatic cancer; Lilly's consensus is a Strong Buy from 20 analysts with a $1,375.78 average target. Boeing (BA) slipped 0.43% even after the FAA concluded that a recently found software glitch is not a flight-safety issue, reopening the path to 737 MAX 10 certification. Morgan Stanley (MS) reiterated an Outperform rating and $300 target on SpaceX, outside the tracked universe, which rose more than 5%. As always: a price target is one firm's estimate rather than a forecast of what a stock will do, a reported takeover price can change before closing, and none of this is a recommendation to buy or sell anything.

Tickers in this brief

Published 2026-10-05. Market commentary, not investment advice. Prices are delayed end-of-day data.